Jeffrey Walsh
Primary Care · Bountiful, UTNPI 1962070102
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.7%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 37 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 31.7% of the total. 2025 is the largest year on record at $8,914, more than ten times the $253 reported in 2022. Among primary care clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 375 payments — averaging $39.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$5K
- Jazz Pharmaceuticals Inc.$4K
- AstraZeneca$1K
- Avadel CNS Pharmaceuticals, LLC$547
- Harmony Biosciences LLC$512
- GSK$426
- plus $3K from 31 others
What the payments were for
- Consulting fees$3002%
- Speaking & faculty fees$2,37616%
- Travel & lodging$3,55224%
- Food & beverage$7,88554%
- Education$5614%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 62 | $4,647 |
| Jazz Pharmaceuticals Inc. | 17 | $4,037 |
| AstraZeneca | 42 | $1,218 |
| Avadel CNS Pharmaceuticals, LLC | 38 | $547 |
| Harmony Biosciences LLC | 27 | $512 |
| GSK | 27 | $426 |
| Mylan Specialty L.p. | 19 | $269 |
| Grifols USA, LLC | 12 | $266 |
| United Therapeutics Corporation | 9 | $259 |
| Sanofi-aventis U.S. LLC | 3 | $246 |
| Axsome Therapeutics, Inc. | 13 | $239 |
| Actelion Pharmaceuticals US, Inc. | 10 | $232 |
| Amgen | 8 | $183 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $166 |
| Viatris Specialty LLC | 11 | $161 |
| Baxter Healthcare | 9 | $160 |
| Sanofi | 6 | $105 |
| Philips North America LLC | 6 | $103 |
| Merck | 6 | $91 |
| ANI Pharmaceuticals, Inc. | 4 | $87 |
| Resmed Corp | 5 | $81 |
| Boehringer Ingelheim | 4 | $77 |
| Idorsia Pharmaceuticals US Inc | 4 | $74 |
| Vifor Pharma, Inc. | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 3 | $65 |
| Electromed, Inc. | 4 | $58 |
| Bayer | 3 | $47 |
| Pulmonx Corporation | 1 | $39 |
| Verona Pharma, Inc. | 2 | $37 |
| 3b Medical, Inc. | 2 | $30 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Lilly USA, LLC | 2 | $28 |
| AbbVie | 1 | $21 |
| Itamar Medical Inc | 1 | $19 |
| ZOLL Respicardia, Inc. | 1 | $18 |
| Novo Nordisk | 1 | $16 |
| Insmed, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,675 in reported general payments places this provider in the 95th percentile of 60 primary care providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 91 | $65,647 |
| Dupixent PenDupilumab | 14 | $52,389 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $44,445 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $11,041 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $9,768 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 17 | $8,181 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $6,114 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $1,380 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 54 | $1,095 |
| Montelukast Sodium | 46 | $346 |
| Eszopiclone | 13 | $97 |
| Trazodone Hcl | 22 | $80 |
| Prednisone | 18 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere, Symbicort | $1,218 | $75,414123 claims |
| GSKTrelegy Ellipta | $426 | $44,44558 claims |
| Boehringer IngelheimCombivent Respimat, Stiolto Respimat | $77 | $14,29530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 60 primary care providers in Utah.
Other primary care in Bountiful
- Holly WortleyBountiful$3K
- London JacksonSpringville$22K
- Tyler HobbsProvo$15K
- Marcella RowleyRiverton$13K
- Elizabeth WillmoreRiverton$6K
- Dustin ThompsonLayton$6K
- Catherine CoatesSalt Lake City$5K
- Liana KinikiniWest Jordan$4K
- Stacey LakeHolladay$3K
- Madeleine RupertSalt Lake City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.